With this ever-progressing field in neurodegenerative disease drug development, the design of protein degradation therapies has gained huge amounts of momentum. With the first patient dosed by Arvinas, the movement towards clinic has rapidly changed the focus of the field towards translating towards Phase I trials.

Be a part of the future of protein degradation for CNS diseases by keeping your knowledge up-to-date at the 2nd Protein Degradation for CNS Summit, returning to Boston for its 2nd year running. Hear the latest findings in degrader design, target identification, mechanism selection and PKPD considerations at this industry-leading conference, with expert speakers from Arvinas, Biogen and Monte Rosa Therapeutics.

Event link here.